Boehringer Ingelheim Drug Patent Portfolio
Boehringer Ingelheim owns 26 orange book drugs protected by 186 US patents with Aggrenox having the least patent protection, holding only 1 patent. And Spiriva Respimat with maximum patent protection, holding 39 patents. Given below is the list of Boehringer Ingelheim's drug patents along with their expiration dates.
Drug Patent Number | Drug Patent Title | Drug Patent Expiry | Status |
---|---|---|---|
US9949998 | Pharmaceutical composition, methods for treating and uses thereof | 11 Dec, 2034 | Active |
US9949997 | Pharmaceutical composition, methods for treating and uses thereof | 17 Nov, 2034 | Active |
US10258637 | Pharmaceutical composition, methods for treating and uses thereof | 03 Oct, 2034 | Active |
US11090323 | Pharmaceutical composition, methods for treating and uses thereof | 03 Oct, 2034 | Active |
US9949998 | Pharmaceutical composition, methods for treating and uses thereof | 11 Jun, 2034 | Active |
US9949997 | Pharmaceutical composition, methods for treating and uses thereof | 17 May, 2034 | Active |
US10258637 | Pharmaceutical composition, methods for treating and uses thereof | 03 Apr, 2034 | Active |
US11090323 | Pharmaceutical composition, methods for treating and uses thereof | 03 Apr, 2034 | Active |
US11833166 | Pharmaceutical composition, methods for treating and uses thereof | 03 Apr, 2034 | Active |
US11666590 | Pharmaceutical composition, methods for treating and uses thereof | 03 Apr, 2034 | Active |
US11813275 | Pharmaceutical composition, methods for treating and uses thereof | 03 Apr, 2034 | Active |
US9555001 | Pharmaceutical composition and uses thereof | 06 Sep, 2033 | Active |
US9555001 | Pharmaceutical composition and uses thereof | 06 Mar, 2033 | Active |
US10596120 | Pharmaceutical compositions | 07 Sep, 2032 | Active |
US10596120 | Pharmaceutical compositions | 07 Mar, 2032 | Active |
US11564886 | Pharmaceutical compositions | 07 Mar, 2032 | Active |
US8853156 | Treatment for diabetes in patients inappropriate for metformin therapy | 05 Sep, 2031 | Active |
US9034822 | Methods of using antibodies during anticoagulant therapy of dabigatran and/or related compounds | 20 Jul, 2031 | Active |
US8733341 | Atomizer and method of atomizing fluid with a nozzle rinsing mechanism | 16 Apr, 2031 | Active |
US10610489 | Pharmaceutical composition, pharmaceutical dosage form, process for their preparation, methods for treating and uses thereof | 30 Mar, 2031 | Active |
US8853156 | Treatment for diabetes in patients inappropriate for metformin therapy | 05 Mar, 2031 | Active |
US9034822 | Methods of using antibodies during anticoagulant therapy of dabigatran and/or related compounds | 20 Jan, 2031 | Active |
US10004743 | Process for drying of BIBW2992, of its salts and of solid pharmaceutical formulations comprising this active ingredient | 05 Jan, 2031 | Active |
US8846695 | Treatment for diabetes in patients with inadequate glycemic control despite metformin therapy comprising a DPP-IV inhibitor | 04 Dec, 2030 | Active |
US9155705 | DPP-IV inhibitor combined with a further antidiabetic agent, tablets comprising such formulations, their use and process for their preparation | 21 Nov, 2030 | Active |
US8733341 | Atomizer and method of atomizing fluid with a nozzle rinsing mechanism | 16 Oct, 2030 | Active |
US10610489 | Pharmaceutical composition, pharmaceutical dosage form, process for their preparation, methods for treating and uses thereof | 30 Sep, 2030 | Active |
US10004743 | Process for drying of BIBW2992, of its salts and of solid pharmaceutical formulations comprising this active ingredient | 05 Jul, 2030 | Active |
US8545884 | Solid pharmaceutical formulations comprising BIBW 2992 | 19 Jun, 2030 | Active |
US10406172 | Pharmaceutical composition, methods for treating and uses thereof | 15 Jun, 2030 | Active |
US8846695 | Treatment for diabetes in patients with inadequate glycemic control despite metformin therapy comprising a DPP-IV inhibitor | 04 Jun, 2030 | Active |
US9155705 | DPP-IV inhibitor combined with a further antidiabetic agent, tablets comprising such formulations, their use and process for their preparation | 21 May, 2030 | Active |
US9010323 | Inhaler and sieve for an inhaler | 19 Apr, 2030 | Active |
US8551957 | Pharmaceutical composition comprising a glucopyranosyl-substituted benzene derivate | 14 Apr, 2030 | Active |
US8426586 | Process for preparing amino crotonyl compounds | 10 Apr, 2030 | Active |
US11911388 | Treatment for diabetes in patients with insufficient glycemic control despite therapy with an oral or non-oral antidiabetic drug | 10 Apr, 2030 | Active |
US10034877 | Treatment for diabetes in patients inappropriate for metformin therapy | 05 Feb, 2030 | Active |
US9486526 | Treatment for diabetes in patients inappropriate for metformin therapy | 05 Feb, 2030 | Active |
US8474447 | Inhaler device | 17 Jan, 2030 | Active |
US8545884 | Solid pharmaceutical formulations comprising BIBW 2992 | 19 Dec, 2029 | Active |
US9907756 | Capsule pharmaceutical dosage form comprising a suspension formulation of an indolinone derivative | 07 Dec, 2029 | Active |
US10105323 | Pharmaceutical dosage form for immediate release of an indolinone derivative | 04 Dec, 2029 | Active |
US8551957 | Pharmaceutical composition comprising a glucopyranosyl-substituted benzene derivate | 14 Oct, 2029 | Active |
US8426586 | Process for preparing amino crotonyl compounds | 10 Oct, 2029 | Active |
US10022379 | DPP-IV inhibitor combined with a further antidiabetic agent, tablets comprising such formulations, their use and process for their preparation | 02 Oct, 2029 | Active |
US10973827 | DPP-IV inhibitor combined with a further antidiabetic agent, tablets comprising such formulations, their use and process for their preparation | 02 Oct, 2029 | Active |
US9415016 | DPP-IV inhibitor combined with a further antidiabetic agent, tablets comprising such formulations, their use and process for their preparation | 02 Oct, 2029 | Active |
US8679533 | Pramipexole once-daily dosage form | 08 Sep, 2029 | Active |
US10034877 | Treatment for diabetes in patients inappropriate for metformin therapy | 05 Aug, 2029 | Active |
US9486526 | Treatment for diabetes in patients inappropriate for metformin therapy | 05 Aug, 2029 | Active |
US9907756 | Capsule pharmaceutical dosage form comprising a suspension formulation of an indolinone derivative | 07 Jun, 2029 | Active |
US10105323 | Pharmaceutical dosage form for immediate release of an indolinone derivative | 04 Jun, 2029 | Active |
US10022379 | DPP-IV inhibitor combined with a further antidiabetic agent, tablets comprising such formulations, their use and process for their preparation | 02 Apr, 2029 | Active |
US10973827 | DPP-IV inhibitor combined with a further antidiabetic agent, tablets comprising such formulations, their use and process for their preparation | 02 Apr, 2029 | Active |
US9415016 | DPP-IV inhibitor combined with a further antidiabetic agent, tablets comprising such formulations, their use and process for their preparation | 02 Apr, 2029 | Active |
US8460704 | Extended release formulation of nevirapine | 12 Mar, 2029 | Active |
US7579449 | Glucopyranosyl-substituted phenyl derivatives, medicaments containing such compounds, their use and process for their manufacture | 01 Feb, 2029 | Active |
US7837235 | Device for clamping a fluidic component | 13 Sep, 2028 | Active |
US7579449 | Glucopyranosyl-substituted phenyl derivatives, medicaments containing such compounds, their use and process for their manufacture | 01 Aug, 2028 | Active |
US7695734 | Extended release tablet formulation containing pramipexole or a pharmaceutically acceptable salt thereof | 26 Apr, 2028 | Active |
US7837235 | Device for clamping a fluidic component | 13 Mar, 2028 | Active |
US7866474 | Film container | 02 Mar, 2028 | Active |
US11033552 | DPP IV inhibitor formulations | 04 Nov, 2027 | Active |
US8673927 | Uses of DPP-IV inhibitors | 04 Nov, 2027 | Active |
US9173859 | Uses of DPP IV inhibitors | 04 Nov, 2027 | Active |
US7713938 | Crystalline form of 1-chloro-4-(β-D-glucopyranos-1-yl)-2-[4-((S)-tetrahydrofuran-3-yloxy)-benzyl]-benzene, a method for its preparation and the use thereof for preparing medicaments | 15 Oct, 2027 | Active |
US9027967 | Device for clamping a fluidic component | 30 Sep, 2027 | Active |
US7694676 | Dry powder inhaler | 12 Sep, 2027 | Active |
US7866474 | Film container | 31 Aug, 2027 | Active |
US9539258 | Quinazoline derivatives for the treatment of cancer diseases | 09 May, 2027 | Active |
US11033552 | DPP IV inhibitor formulations | 04 May, 2027 | Active |
US8673927 | Uses of DPP-IV inhibitors | 04 May, 2027 | Active |
US9173859 | Uses of DPP IV inhibitors | 04 May, 2027 | Active |
US7713938 | Crystalline form of 1-chloro-4-(β-D-glucopyranos-1-yl)-2-[4-((S)-tetrahydrofuran-3-yloxy)-benzyl]-benzene, a method for its preparation and the use thereof for preparing medicaments | 15 Apr, 2027 | Active |
US7396341 | Blocking device for a locking stressing mechanism having a spring-actuated output drive device | 10 Apr, 2027 | Active |
US9027967 | Device for clamping a fluidic component | 31 Mar, 2027 | Active |
US7694676 | Dry powder inhaler | 12 Mar, 2027 | Active |
US7727984 | Medicaments for the treatment of chronic obstructive pulmonary disease | 19 Jan, 2027 | Active |
US9539258 | Quinazoline derivatives for the treatment of cancer diseases | 09 Nov, 2026 | Active |
US7396341 | Blocking device for a locking stressing mechanism having a spring-actuated output drive device | 10 Oct, 2026 | Active |
US8022082 | Method for the administration of an anticholinergic by inhalation | 19 Jul, 2026 | Active |
USRE43431 | Quinazoline derivatives and pharmaceutical compositions containing them | 13 Jul, 2026 | Active |
US10154990 | Medicaments for the treatment or prevention of fibrotic diseases | 08 Jul, 2026 | Active |
US8883805 | Process for the preparation of chiral 8-(3-aminopiperidin-1-yl)-xanthines | 26 May, 2026 | Active |
US6762180 | Substituted indolines which inhibit receptor tyrosine kinases | 01 Apr, 2026 | Active |
US7932273 | 3-[(2-{[4-(hexyloxycarbonylaminoiminomethyl) phenylamino]methyl}-1-methyl-1H-benzimidazol-5-carbonyl)pyridin-2-ylamino]propionic acid ethylester methansulfonate and its use as a medicament | 07 Mar, 2026 | Active |
US8022082 | Method for the administration of an anticholinergic by inhalation | 19 Jan, 2026 | Active |
USRE43431 | Quinazoline derivatives and pharmaceutical compositions containing them | 13 Jan, 2026 | Active |
US10154990 | Medicaments for the treatment or prevention of fibrotic diseases | 08 Jan, 2026 | Active |
US8883805 | Process for the preparation of chiral 8-(3-aminopiperidin-1-yl)-xanthines | 26 Nov, 2025 | Active |
US7896264 | Microstructured high pressure nozzle with built-in filter function | 26 Nov, 2025 | Active |
US7407955 | 8-[3-amino-piperidin-1-yl]-xanthines, the preparation thereof and their use as pharmaceutical compositions | 02 Nov, 2025 | Active |
US6762180 | Substituted indolines which inhibit receptor tyrosine kinases | 01 Oct, 2025 | Active |
US7932273 | 3-[(2-{[4-(hexyloxycarbonylaminoiminomethyl) phenylamino]methyl}-1-methyl-1H-benzimidazol-5-carbonyl)pyridin-2-ylamino]propionic acid ethylester methansulfonate and its use as a medicament | 07 Sep, 2025 | Active |
US7896264 | Microstructured high pressure nozzle with built-in filter function | 26 May, 2025 | Active |
US7220742 | Enantiomerically pure beta agonists, process for the manufacture thereof and use thereof as medicaments | 12 May, 2025 | Active |
US8034809 | Enantiomerically pure beta agonists, process for the manufacture thereof and use thereof as medicaments | 12 May, 2025 | Active |
US7407955 | 8-[3-amino-piperidin-1-yl]-xanthines, the preparation thereof and their use as pharmaceutical compositions | 02 May, 2025 | Active |
US7284474 | Piston-pumping system having o-ring seal properties | 26 Feb, 2025 | Active |
US7284474 | Piston-pumping system having o-ring seal properties | 26 Aug, 2024 | Expired |
US7989474 | Use of Lck inhibitors for treatment of immunologic diseases | 06 Apr, 2024 | Expired |
US7119093 | 3-Z-[1-(4-(N-((4-Methyl-piperazin-1-yl)-methylcarbonyl)-N-methyl-amino)-anilino)-1-phenyl-methylene]-6-methoxycarbonyl-2-indolinone-monoethanesulphonate and the use thereof as a pharmaceutical composition | 21 Feb, 2024 | Expired |
US9925174 | Administration form for the oral application of 3-[(2-{[4-(hexyloxycarbonyl-amino-imino-methyl)-phenylamino]-methyl}-1-methyl-1 H-benzimidazol acid ethyl ester and the salts thereof | 14 Dec, 2023 | Expired |
US7056916 | Medicaments for the treatment of chronic obstructive pulmonary disease | 07 Dec, 2023 | Expired |
US7491719 | Enantiomerically pure beta agonists, process for the manufacture thereof, and use thereof as medicaments | 10 Nov, 2023 | Expired |
US7786111 | Medicaments for the treatment of chronic obstructive pulmonary disease | 10 Nov, 2023 | Expired |
US8044046 | Medicaments for the treatment of chronic obstructive pulmonary disease | 10 Nov, 2023 | Expired |
US8119648 | 8-[3-amino-piperidin-1-yl]-xanthines, the preparation thereof and their use as pharmaceutical compositions | 12 Aug, 2023 | Expired |
US8178541 | 8-[3-amino-piperidin-1-yl]-xanthines, the preparation thereof and their use as pharmaceutical compositions | 12 Aug, 2023 | Expired |
US9925174 | Administration form for the oral application of 3-[(2-{[4-(hexyloxycarbonyl-amino-imino-methyl)-phenylamino]-methyl}-1-methyl-1 H-benzimidazol acid ethyl ester and the salts thereof | 14 Jun, 2023 | Expired |
US8003679 | Use of inhibitors of the renin-angiotensin system | 06 Oct, 2022 | Expired |
US7070800 | Inhalable powder containing tiotropium | 22 Jul, 2022 | Expired |
US6087380 | Disubstituted bicyclic heterocycles, the preparations and the use thereof as pharmaceutical compositions | 28 Jun, 2022 | Expired |
USRE38912 | Process for preparing powder formulations | 11 Apr, 2022 | Expired |
US6777423 | Crystalline tiotropium bromide monohydrate, processes for the preparation thereof, and pharmaceutical compositions | 24 Mar, 2022 | Expired |
US6908928 | Crystalline tiotropium bromide monohydrate, processes for the preparation thereof, and pharmaceutical compositions | 24 Mar, 2022 | Expired |
US7309707 | Crystalline micronisate, process for the manufacture thereof and use thereof for the preparation of a medicament | 24 Mar, 2022 | Expired |
US7642268 | Crystalline micronisate, process for the manufacture thereof and use thereof for the preparation of a medicament | 24 Mar, 2022 | Expired |
US7988001 | Container provided with a pressure equalization opening | 04 Feb, 2022 | Expired |
US7070800 | Inhalable powder containing tiotropium | 22 Jan, 2022 | Expired |
US6087380 | Disubstituted bicyclic heterocycles, the preparations and the use thereof as pharmaceutical compositions | 28 Dec, 2021 | Expired |
USRE38912 | Process for preparing powder formulations | 11 Oct, 2021 | Expired |
US6777423 | Crystalline tiotropium bromide monohydrate, processes for the preparation thereof, and pharmaceutical compositions | 24 Sep, 2021 | Expired |
US6908928 | Crystalline tiotropium bromide monohydrate, processes for the preparation thereof, and pharmaceutical compositions | 24 Sep, 2021 | Expired |
US7309707 | Crystalline micronisate, process for the manufacture thereof and use thereof for the preparation of a medicament | 24 Sep, 2021 | Expired |
US7642268 | Crystalline micronisate, process for the manufacture thereof and use thereof for the preparation of a medicament | 24 Sep, 2021 | Expired |
US7988001 | Container provided with a pressure equalization opening | 04 Aug, 2021 | Expired |
US6988496 | Cartridge for a liquid | 23 Aug, 2020 | Expired |
US6488962 | Tablet shapes to enhance gastric retention of swellable controlled-release oral dosage forms | 20 Jun, 2020 | Expired |
US7998953 | Use of inhibitors of the renin-angiotensin system | 06 Jun, 2020 | Expired |
US6739333 | Stainless steel canister for propellant-driven metering aerosols | 26 May, 2020 | Expired |
US6983743 | Stainless steel canister for propellant-driven metering aerosols | 26 May, 2020 | Expired |
US6147095 | Method for improving the pharmacokinetics of tipranavir | 29 Apr, 2020 | Expired |
US6988496 | Cartridge for a liquid | 23 Feb, 2020 | Expired |
US6358986 | Polymorphs of telmisartan | 10 Jan, 2020 | Expired |
US5852195 | Pyranone compounds useful to treat retroviral infections | 22 Dec, 2019 | Expired |
US6147095 | Method for improving the pharmacokinetics of tipranavir | 29 Oct, 2019 | Expired |
US7802568 | Cartridge for a liquid | 26 Aug, 2019 | Expired |
US5852195 | Pyranone compounds useful to treat retroviral infections | 22 Jun, 2019 | Expired |
US6846413 | Microstructured filter | 28 Feb, 2019 | Expired |
US6977042 | Microstructured filter | 28 Feb, 2019 | Expired |
US7802568 | Cartridge for a liquid | 26 Feb, 2019 | Expired |
US6890898 | Method of regulating glucose metabolism, and reagents related thereto | 02 Feb, 2019 | Expired |
US7078381 | Method of regulating glucose metabolism, and reagents related thereto | 02 Feb, 2019 | Expired |
US7459428 | Method of regulating glucose metabolism, and reagents related thereto | 02 Feb, 2019 | Expired |
US6231887 | Pharmaceutical composition for acidic lipophilic compounds in a form of a self-emulsifying formulation | 27 Jan, 2019 | Expired |
US6846413 | Microstructured filter | 28 Aug, 2018 | Expired |
US6977042 | Microstructured filter | 28 Aug, 2018 | Expired |
USRE39820 | Esters of thienyl carboxylic acids and amino alcohols and their quaternization products | 30 Jul, 2018 | Expired |
US6251912 | Substituted quinazoline derivatives | 29 Jul, 2018 | Expired |
US6231887 | Pharmaceutical composition for acidic lipophilic compounds in a form of a self-emulsifying formulation | 27 Jul, 2018 | Expired |
USRE39820 | Esters of thienyl carboxylic acids and amino alcohols and their quaternization products | 30 Jan, 2018 | Expired |
US6001861 | Use of pramipexole in the treatment of restless legs syndrome | 16 Jan, 2018 | Expired |
US6194445 | Use of pramipexole in the treatment of restless legs syndrome | 16 Jan, 2018 | Expired |
US6149054 | Mechanical counter for a metering apparatus | 19 Jun, 2017 | Expired |
US6453795 | Locking mechanism for a spring-actuated device | 05 Jun, 2017 | Expired |
US6303661 | Use of dipeptidyl peptidase IV effectors for lowering the blood glucose level in mammals | 24 Apr, 2017 | Expired |
US5964416 | Device for producing high pressure in a fluid in miniature | 04 Apr, 2017 | Expired |
US6726124 | Device for producing high pressure in a fluid in miniature | 04 Apr, 2017 | Expired |
US7104470 | Device for producing high pressure in a fluid in miniature | 04 Apr, 2017 | Expired |
US6015577 | Pharmaceutical compositions containing dipyridamole or mopidamol and acetylsalicylic acid or the physiologically acceptable salts thereof, processes for preparing them and their use in treating clot formation | 18 Jan, 2017 | Expired |
US6149054 | Mechanical counter for a metering apparatus | 19 Dec, 2016 | Expired |
US6453795 | Locking mechanism for a spring-actuated device | 05 Dec, 2016 | Expired |
US6176442 | Device for mounting a component exposed to a pressurized fluid | 01 Dec, 2016 | Expired |
US7246615 | Atomising nozzle and filter and spray generating device | 01 Dec, 2016 | Expired |
US5964416 | Device for producing high pressure in a fluid in miniature | 04 Oct, 2016 | Expired |
US6176442 | Device for mounting a component exposed to a pressurized fluid | 04 Oct, 2016 | Expired |
US6726124 | Device for producing high pressure in a fluid in miniature | 04 Oct, 2016 | Expired |
US7104470 | Device for producing high pressure in a fluid in miniature | 04 Oct, 2016 | Expired |
US6340475 | Extending the duration of drug release within the stomach during the fed mode | 19 Sep, 2016 | Expired |
US6635280 | Extending the duration of drug release within the stomach during the fed mode | 19 Sep, 2016 | Expired |
US7246615 | Atomising nozzle and filter and spray generating device | 31 May, 2016 | Expired |
US6176242 | Method of treating manic depression by brain infusion | 31 May, 2016 | Expired |
US5603918 | Aerosol composition of a salt of ipratropium and a salt of albuterol | 09 Jun, 2015 | Expired |
US6169181 | Compounds useful to treat retroviral infections | 06 Nov, 2014 | Expired |
US5683677 | Medicinal aerosol formulations | 04 Nov, 2014 | Expired |
US5676930 | Stabilized medicinal aerosol solution formulations | 14 Oct, 2014 | Expired |
US5662271 | Atomizing devices and methods | 02 Sep, 2014 | Expired |
US6169181 | Compounds useful to treat retroviral infections | 06 May, 2014 | Expired |
US5591762 | Benzimidazoles useful as angiotensin-11 antagonists | 07 Jan, 2014 | Expired |
US5472143 | Atomising nozzle and filter and spray generation device | 29 Sep, 2013 | Expired |
US5911851 | Atomizing nozzle and filter and spray generating device | 29 Sep, 2013 | Expired |
US6007676 | Atomizing nozzle and filter and spray generating device | 29 Sep, 2013 | Expired |
US6503362 | Atomizing nozzle an filter and spray generating device | 29 Sep, 2013 | Expired |
US5497944 | Atomising devices and methods | 12 Mar, 2013 | Expired |
US5478578 | Powders for inhalation | 26 Dec, 2012 | Expired |
Latest Legal Activities on Boehringer Ingelheim's Drug Patents
Given below is the list of recent legal activities going on the following drug patents of Boehringer Ingelheim.
Activity | Date | Patent Number |
---|---|---|
Payment of Maintenance Fee, 8th Year, Large Entity | 05 Jul, 2024 | US9539258 |
Expire Patent
Critical
| 17 Jun, 2024 | US8178541 |
Expire Patent
Critical
| 17 Jun, 2024 | US8178541 |
Expire Patent
Critical
| 17 Jun, 2024 | US8178541 |
Payment of Maintenance Fee, 8th Year, Large Entity | 02 May, 2024 | US9486526 |
Expire Patent
Critical
| 25 Mar, 2024 | US8119648 |
Expire Patent
Critical
| 25 Mar, 2024 | US8119648 |
Expire Patent
Critical
| 25 Mar, 2024 | US8119648 |
Email Notification
Critical
| 27 Feb, 2024 | US11911388 |
Patent Issue Date Used in PTA Calculation
Critical
| 27 Feb, 2024 | US11911388 |
Recordation of Patent Grant Mailed
Critical
| 27 Feb, 2024 | US11911388 |
Recordation of Patent Grant Mailed
Critical
| 27 Feb, 2024 | US11911388 |
Patent Issue Date Used in PTA Calculation
Critical
| 27 Feb, 2024 | US11911388 |
Email Notification
Critical
| 27 Feb, 2024 | US11911388 |
Recordation of Patent eGrant | 27 Feb, 2024 | US11911388 |
Boehringer Ingelheim's Drug Patent Litigations
Boehringer Ingelheim's drugs have been subject to various legal proceedings, including patent litigations. The earliest legal proceeding was initiated on Sep 26, 2011, against patent number US8679533. The petitioner , challenged the validity of this patent, with Ernest J. Lee et al as the respondent. Click below to track the latest information on how companies are challenging Boehringer Ingelheim's patents.
Patent | Proceeding Filing Date | Status | Respondent | Petitioner |
---|---|---|---|---|
US8853156 | August, 2016 |
Terminated
(01 Aug, 2017)
| Boehringer Ingelheim Pharmaceuticals Inc. et al. | Mylan Pharmaceuticals Inc. et al. |
US8673927 | August, 2016 |
Terminated
(18 Jul, 2017)
| Boehringer Ingelheim Pharmaceuticals Inc. et al. | Mylan Pharmaceuticals Inc. et al. |
US8846695 | August, 2016 |
Terminated
(18 Jul, 2017)
| Boehringer Ingelheim Pharmaceuticals Inc. et al. | Mylan Pharmaceuticals Inc. et al. |
US9173859 | August, 2016 |
Terminated-Denied
(03 Feb, 2017)
| Boehringer Ingelheim Pharmaceuticals Inc. | Mylan Pharmaceuticals Inc. |
US6340475 | April, 2014 |
Final Written Decision
(21 Sep, 2015)
| Depomed, Inc. | Endo Pharmaceutical Inc. et al. |
US6635280 | April, 2014 |
Final Written Decision
(21 Sep, 2015)
| Depomed, Inc. | Endo Pharmaceutical Inc. et al. |
US6340475 | January, 2014 |
FWD Entered
(08 Jul, 2015)
| Depomed, Inc. | Purdue Pharma L.P. |
US6635280 | January, 2014 |
FWD Entered
(08 Jul, 2015)
| DepoMed, Inc. | Purdue Pharma L.P. |
US6340475 | April, 2014 |
Institution Denied
(29 Sep, 2014)
| Depomed, Inc. | Endo Pharmaceutical Inc. et al. |
US6635280 | April, 2014 |
Institution Denied
(29 Sep, 2014)
| Depomed, Inc. | Endo Pharmaceutical Inc. et al. |
US8679533 | September, 2011 |
Decision
(22 Oct, 2013)
| Ernest J. Lee et al |
Boehringer Ingelheim Drug Patents' Oppositions Filed in EPO
Boehringer Ingelheim drug patents have faced multiple oppositions in the European Patent Office. The earliest opposition was filed on Feb 06, 2006, by Speedel Pharma Ag. This opposition was filed on patent number EP98947698A. Click below to reveal the latest opposition data.
Application | Filing Date | Opposition Party | Legal Status |
---|---|---|---|
EP11179908A | Apr, 2023 | Generics [UK] Limited | Granted and Under Opposition |
EP11179908A | Apr, 2023 | STADA Arzneimittel AG | Granted and Under Opposition |
EP11179908A | Apr, 2023 | Kraus & Weisert Patentanwälte PartGmbB | Granted and Under Opposition |
EP14715274A | Apr, 2023 | TEVA PHARMACEUTICAL INDUSTRIES, LTD. | Granted and Under Opposition |
EP11179908A | Apr, 2023 | ZAKLADY FARMACEUTYCZNE POLPHARMA S.A. | Granted and Under Opposition |
EP11179908A | Apr, 2023 | Sandoz AG | Granted and Under Opposition |
EP10703288A | Jan, 2021 | Generics (U.K.) Limited | Granted and Under Opposition |
EP10703288A | Jan, 2021 | STADA Arzneimittel AG | Granted and Under Opposition |
EP10703288A | Dec, 2020 | ZAKLADY FARMACEUTYCZNE POLPHARMA S.A. | Granted and Under Opposition |
EP11194615A | Jun, 2020 | ELKINGTON AND FIFE LLP | Granted and Under Opposition |
EP10730454A | Dec, 2019 | Generics [UK] Ltd | Granted and Under Opposition |
EP10730454A | Dec, 2019 | LEK Pharmaceuticals d.d. | Granted and Under Opposition |
EP10730454A | Nov, 2019 | Teva Pharmaceutical Industries Ltd | Granted and Under Opposition |
EP09757601A | Aug, 2019 | Teva Pharmaceutical Industries Ltd | Granted and Under Opposition |
EP09757601A | Aug, 2019 | Ter Meer Steinmeister & Partner Patentanwälte mbB | Granted and Under Opposition |
EP09757601A | Aug, 2019 | Generics (U.K.) Limited | Granted and Under Opposition |
EP14715578A | Aug, 2019 | Generics (U.K.) Limited | Granted and Under Opposition |
EP14715578A | Aug, 2019 | Teva Pharmaceutical Industries Ltd | Granted and Under Opposition |
EP14715578A | Aug, 2019 | ZAKLADY FARMACEUTYCZNE POLPHARMA S.A. | Granted and Under Opposition |
EP14715578A | Aug, 2019 | Gillard, Richard Edward | Granted and Under Opposition |
EP14715578A | Aug, 2019 | Stada-Arzneimittel Aktiengesellschaft | Granted and Under Opposition |
EP14715578A | Aug, 2019 | EGIS Gyógyszergyár Zártkörüen Müködö Részvénytársaság | Granted and Under Opposition |
EP14715578A | Aug, 2019 | Alfred E. Tiefenbacher (GmbH & Co. KG) | Granted and Under Opposition |
EP14715578A | Aug, 2019 | KRKA, d.d., Novo mesto | Granted and Under Opposition |
EP09728065A | Jun, 2019 | isarpatent - Patent- und Rechtsanwälte Behnisch Barth Charles Hassa Peckmann und Partner mbB | Revoked |
EP09728065A | Jun, 2019 | Galenicum Health S.L.U. | Revoked |
EP09728065A | Jun, 2019 | Hexal AG | Revoked |
EP09728065A | Jun, 2019 | HGF Limited | Revoked |
EP09757593A | Nov, 2018 | Zentiva Group, a.s. | Granted and Under Opposition |
EP09757593A | Nov, 2018 | Generics (U.K.) Limited | Granted and Under Opposition |
EP09757593A | Nov, 2018 | Galenicum Health S.L. | Granted and Under Opposition |
EP09757593A | Nov, 2018 | Teva Pharmaceutical Industries Ltd | Granted and Under Opposition |
EP08787264A | Jul, 2017 | ZAKLADY FARMACEUTYCZNE POLPHARMA S.A. | Granted and Under Opposition |
EP08787264A | Jul, 2017 | STADA Arzneimittel AG | Granted and Under Opposition |
EP08787264A | Jul, 2017 | Hexal AG | Granted and Under Opposition |
EP08787264A | Jul, 2017 | Generics (U.K.) Limited | Granted and Under Opposition |
EP08756672A | Dec, 2016 | FRKelly | Revoked |
EP12155662A | Sep, 2016 | LEK Pharmaceuticals d.d. | Patent maintained as amended |
EP10175188A | Dec, 2015 | Generics (UK) Limited | Revoked |
EP10175188A | Dec, 2015 | Galenicum Health S.L. | Revoked |
EP10175188A | Dec, 2015 | Hexal AG | Revoked |
EP10175188A | Dec, 2015 | STADA Arzneimittel AG | Revoked |
EP10175188A | Dec, 2015 | Teva Pharmaceutical Industries LTD. | Revoked |
EP10175638A | Jul, 2015 | Generics [UK] Limited (trading as Mylan) | Revoked |
EP10175638A | Jul, 2015 | STADA Arzneimittel AG | Revoked |
EP10175638A | Jul, 2015 | Hexal AG | Revoked |
EP10175638A | Jul, 2015 | Teva Pharmaceutical Industries Ltd. | Revoked |
EP07728723A | Jan, 2015 | Hexal AG | Revoked |
EP03771959A | Jun, 2014 | Maiwald Patentanwalts GmbH | Opposition rejected |
EP03745781A | May, 2014 | Actavis Group PTC ehf | Revoked |
EP03745781A | May, 2014 | Vossius & Partner | Revoked |
EP03745781A | May, 2014 | Teva UK Limited | Revoked |
EP05737938A | Apr, 2014 | Aechter, Bernd | Opposition rejected |
EP03771959A | Oct, 2013 | Actavis Group PTC ehf | Opposition rejected |
EP05823930A | Aug, 2013 | SANDOZ AG | Opposition rejected |
EP03743368A | Apr, 2013 | Sanovel IIaç San. ve Tic. A.S. | Patent maintained as amended |
EP03743368A | Mar, 2013 | Stötter, Gerd | Patent maintained as amended |
EP07115663A | Oct, 2012 | Sanovel IIaç San. ve Tic. A.S. | Revoked |
EP07115663A | Oct, 2012 | Stötter, Gerd | Revoked |
EP05763065A | Aug, 2012 | Dr. May, Mark Andrew | Patent maintained as amended |
EP09153155A | Jul, 2012 | PONS PATENTES Y MARCAS INTERNACIONAL, S.L. | Revoked |
EP09153155A | Jul, 2012 | Sanovel Ilac Sanayii ve Ticaret A.S. | Revoked |
EP09153155A | Jul, 2012 | Stötter, Gerd | Revoked |
EP2004006768W | Apr, 2012 | Knorr-Bremse Systeme für Nutzfahrzeuge GmbH | Revoked |
EP05777774A | Aug, 2011 | Teva Pharmaceutical Industries LTD. | Patent maintained as amended |
EP05777774A | Aug, 2011 | Sölch, Günter | Patent maintained as amended |
EP04764411A | Jan, 2010 | APOTEX INC. | Opposition rejected |
EP04021889A | Apr, 2008 | Merck & Co., Inc. | Revoked |
EP04021889A | Apr, 2008 | Sanofi-Aventis Deutschland GmbH | Revoked |
EP04021889A | Apr, 2008 | TEVA PHARMACEUTICAL INDUSTRIES LTD. | Revoked |
EP04021889A | Apr, 2008 | LES LABORATOIRES SERVIER | Revoked |
EP01986599A | Dec, 2006 | AstraZeneca AB | Patent maintained as amended |
EP01986599A | Dec, 2006 | PFIZER LIMITED | Patent maintained as amended |
EP98947698A | Feb, 2006 | Speedel Pharma AG | Patent maintained as amended |
Boehringer Ingelheim's Family Patents
Boehringer Ingelheim Drug List
Given below is the complete list of Boehringer Ingelheim's drugs and the patents protecting them.
1. Aggrenox
Aggrenox is protected by 1 patent, which has expired already. Check out its patent list below.
Drug Patent Number | Drug Patent Title | Drug Patent Expiry | Status |
---|---|---|---|
US6015577 | Pharmaceutical compositions containing dipyridamole or mopidamol and acetylsalicylic acid or the physiologically acceptable salts thereof, processes for preparing them and their use in treating clot formation |
18 Jan, 2017
(7 years ago)
| Expired |
Discover which of these patents contain the active ingredient(API) of the drug, their family patents, along with litigation and legal activity details of these patents on Aggrenox's drug page
2. Aptivus
Aptivus is protected by 8 patents, out of which all have expired. Check out its patent list below.
Drug Patent Number | Drug Patent Title | Drug Patent Expiry | Status |
---|---|---|---|
US6147095
(Pediatric)
| Method for improving the pharmacokinetics of tipranavir |
29 Apr, 2020
(4 years ago)
| Expired |
US5852195
(Pediatric)
| Pyranone compounds useful to treat retroviral infections |
22 Dec, 2019
(4 years ago)
| Expired |
US6147095 | Method for improving the pharmacokinetics of tipranavir |
29 Oct, 2019
(5 years ago)
| Expired |
US5852195 | Pyranone compounds useful to treat retroviral infections |
22 Jun, 2019
(5 years ago)
| Expired |
US6231887
(Pediatric)
| Pharmaceutical composition for acidic lipophilic compounds in a form of a self-emulsifying formulation |
27 Jan, 2019
(5 years ago)
| Expired |
US6231887 | Pharmaceutical composition for acidic lipophilic compounds in a form of a self-emulsifying formulation |
27 Jul, 2018
(6 years ago)
| Expired |
US6169181
(Pediatric)
| Compounds useful to treat retroviral infections |
06 Nov, 2014
(10 years ago)
| Expired |
US6169181 | Compounds useful to treat retroviral infections |
06 May, 2014
(10 years ago)
| Expired |
Discover which of these patents contain the active ingredient(API) of the drug, their family patents, along with litigation and legal activity details of these patents on Aptivus's drug page
3. Atrovent Hfa
Atrovent Hfa is protected by 5 patents, out of which 4 have expired. Check out its patent list below.
Drug Patent Number | Drug Patent Title | Drug Patent Expiry | Status |
---|---|---|---|
US8474447 | Inhaler device |
17 Jan, 2030
(5 years from now)
| Active |
US6739333 | Stainless steel canister for propellant-driven metering aerosols |
26 May, 2020
(4 years ago)
| Expired |
US6983743 | Stainless steel canister for propellant-driven metering aerosols |
26 May, 2020
(4 years ago)
| Expired |
US5683677 | Medicinal aerosol formulations |
04 Nov, 2014
(10 years ago)
| Expired |
US5676930 | Stabilized medicinal aerosol solution formulations |
14 Oct, 2014
(10 years ago)
| Expired |
Discover which of these patents contain the active ingredient(API) of the drug, their family patents, along with litigation and legal activity details of these patents on Atrovent Hfa's drug page
4. Combivent
Combivent is protected by 1 patent, which has expired already. Check out its patent list below.
Drug Patent Number | Drug Patent Title | Drug Patent Expiry | Status |
---|---|---|---|
US5603918 | Aerosol composition of a salt of ipratropium and a salt of albuterol |
09 Jun, 2015
(9 years ago)
| Expired |
Discover which of these patents contain the active ingredient(API) of the drug, their family patents, along with litigation and legal activity details of these patents on Combivent's drug page
5. Combivent Respimat
Combivent Respimat is protected by 24 patents, out of which 19 have expired. Check out its patent list below.
Drug Patent Number | Drug Patent Title | Drug Patent Expiry | Status |
---|---|---|---|
US8733341 | Atomizer and method of atomizing fluid with a nozzle rinsing mechanism |
16 Oct, 2030
(5 years from now)
| Active |
US7837235 | Device for clamping a fluidic component |
13 Mar, 2028
(3 years from now)
| Active |
US9027967 | Device for clamping a fluidic component |
31 Mar, 2027
(2 years from now)
| Active |
US7396341 | Blocking device for a locking stressing mechanism having a spring-actuated output drive device |
10 Oct, 2026
(1 year, 9 months from now)
| Active |
US7896264 | Microstructured high pressure nozzle with built-in filter function |
26 May, 2025
(5 months from now)
| Active |
US7284474 | Piston-pumping system having o-ring seal properties |
26 Aug, 2024
(3 months ago)
| Expired |
US7988001 | Container provided with a pressure equalization opening |
04 Aug, 2021
(3 years ago)
| Expired |
US6988496 | Cartridge for a liquid |
23 Feb, 2020
(4 years ago)
| Expired |
US7802568 | Cartridge for a liquid |
26 Feb, 2019
(5 years ago)
| Expired |
US6846413 | Microstructured filter |
28 Aug, 2018
(6 years ago)
| Expired |
US6977042 | Microstructured filter |
28 Aug, 2018
(6 years ago)
| Expired |
US6149054 | Mechanical counter for a metering apparatus |
19 Dec, 2016
(8 years ago)
| Expired |
US6453795 | Locking mechanism for a spring-actuated device |
05 Dec, 2016
(8 years ago)
| Expired |
US5964416 | Device for producing high pressure in a fluid in miniature |
04 Oct, 2016
(8 years ago)
| Expired |
US6176442 | Device for mounting a component exposed to a pressurized fluid |
04 Oct, 2016
(8 years ago)
| Expired |
US6726124 | Device for producing high pressure in a fluid in miniature |
04 Oct, 2016
(8 years ago)
| Expired |
US7104470 | Device for producing high pressure in a fluid in miniature |
04 Oct, 2016
(8 years ago)
| Expired |
US7246615 | Atomising nozzle and filter and spray generating device |
31 May, 2016
(8 years ago)
| Expired |
US5662271 | Atomizing devices and methods |
02 Sep, 2014
(10 years ago)
| Expired |
US5472143 | Atomising nozzle and filter and spray generation device |
29 Sep, 2013
(11 years ago)
| Expired |
US5911851 | Atomizing nozzle and filter and spray generating device |
29 Sep, 2013
(11 years ago)
| Expired |
US6007676 | Atomizing nozzle and filter and spray generating device |
29 Sep, 2013
(11 years ago)
| Expired |
US6503362 | Atomizing nozzle an filter and spray generating device |
29 Sep, 2013
(11 years ago)
| Expired |
US5497944 | Atomising devices and methods |
12 Mar, 2013
(11 years ago)
| Expired |
Discover which of these patents contain the active ingredient(API) of the drug, their family patents, along with litigation and legal activity details of these patents on Combivent Respimat's drug page
Explore Our Curated Drug Screens
6. Gilotrif
Gilotrif is protected by 11 patents, out of which 1 has expired. Check out its patent list below.
Drug Patent Number | Drug Patent Title | Drug Patent Expiry | Status |
---|---|---|---|
US10004743
(Pediatric)
| Process for drying of BIBW2992, of its salts and of solid pharmaceutical formulations comprising this active ingredient |
05 Jan, 2031
(6 years from now)
| Active |
US10004743 | Process for drying of BIBW2992, of its salts and of solid pharmaceutical formulations comprising this active ingredient |
05 Jul, 2030
(5 years from now)
| Active |
US8545884
(Pediatric)
| Solid pharmaceutical formulations comprising BIBW 2992 |
19 Jun, 2030
(5 years from now)
| Active |
US8426586
(Pediatric)
| Process for preparing amino crotonyl compounds |
10 Apr, 2030
(5 years from now)
| Active |
US8545884 | Solid pharmaceutical formulations comprising BIBW 2992 |
19 Dec, 2029
(5 years from now)
| Active |
US8426586 | Process for preparing amino crotonyl compounds |
10 Oct, 2029
(4 years from now)
| Active |
US9539258
(Pediatric)
| Quinazoline derivatives for the treatment of cancer diseases |
09 May, 2027
(2 years from now)
| Active |
US9539258 | Quinazoline derivatives for the treatment of cancer diseases |
09 Nov, 2026
(1 year, 10 months from now)
| Active |
USRE43431
(Pediatric)
| Quinazoline derivatives and pharmaceutical compositions containing them |
13 Jul, 2026
(1 year, 6 months from now)
| Active |
USRE43431 | Quinazoline derivatives and pharmaceutical compositions containing them |
13 Jan, 2026
(1 year, 25 days from now)
| Active |
US6251912 | Substituted quinazoline derivatives |
29 Jul, 2018
(6 years ago)
| Expired |
Discover which of these patents contain the active ingredient(API) of the drug, their family patents, along with litigation and legal activity details of these patents on Gilotrif's drug page
7. Glyxambi
Glyxambi is protected by 29 patents, out of which 6 have expired. Check out its patent list below.
Drug Patent Number | Drug Patent Title | Drug Patent Expiry | Status |
---|---|---|---|
US10258637
(Pediatric)
| Pharmaceutical composition, methods for treating and uses thereof |
03 Oct, 2034
(9 years from now)
| Active |
US11090323
(Pediatric)
| Pharmaceutical composition, methods for treating and uses thereof |
03 Oct, 2034
(9 years from now)
| Active |
US9949998 | Pharmaceutical composition, methods for treating and uses thereof |
11 Jun, 2034
(9 years from now)
| Active |
US10258637 | Pharmaceutical composition, methods for treating and uses thereof |
03 Apr, 2034
(9 years from now)
| Active |
US11090323 | Pharmaceutical composition, methods for treating and uses thereof |
03 Apr, 2034
(9 years from now)
| Active |
US11833166 | Pharmaceutical composition, methods for treating and uses thereof |
03 Apr, 2034
(9 years from now)
| Active |
US10406172 | Pharmaceutical composition, methods for treating and uses thereof |
15 Jun, 2030
(5 years from now)
| Active |
US8846695 | Treatment for diabetes in patients with inadequate glycemic control despite metformin therapy comprising a DPP-IV inhibitor |
04 Jun, 2030
(5 years from now)
| Active |
US8551957
(Pediatric)
| Pharmaceutical composition comprising a glucopyranosyl-substituted benzene derivate |
14 Apr, 2030
(5 years from now)
| Active |
US8551957 | Pharmaceutical composition comprising a glucopyranosyl-substituted benzene derivate |
14 Oct, 2029
(4 years from now)
| Active |
US7579449
(Pediatric)
| Glucopyranosyl-substituted phenyl derivatives, medicaments containing such compounds, their use and process for their manufacture |
01 Feb, 2029
(4 years from now)
| Active |
US7579449 | Glucopyranosyl-substituted phenyl derivatives, medicaments containing such compounds, their use and process for their manufacture |
01 Aug, 2028
(3 years from now)
| Active |
US11033552
(Pediatric)
| DPP IV inhibitor formulations |
04 Nov, 2027
(2 years from now)
| Active |
US8673927
(Pediatric)
| Uses of DPP-IV inhibitors |
04 Nov, 2027
(2 years from now)
| Active |
US7713938
(Pediatric)
| Crystalline form of 1-chloro-4-(β-D-glucopyranos-1-yl)-2-[4-((S)-tetrahydrofuran-3-yloxy)-benzyl]-benzene, a method for its preparation and the use thereof for preparing medicaments |
15 Oct, 2027
(2 years from now)
| Active |
US11033552 | DPP IV inhibitor formulations |
04 May, 2027
(2 years from now)
| Active |
US8673927 | Uses of DPP-IV inhibitors |
04 May, 2027
(2 years from now)
| Active |
US9173859 | Uses of DPP IV inhibitors |
04 May, 2027
(2 years from now)
| Active |
US7713938 | Crystalline form of 1-chloro-4-(β-D-glucopyranos-1-yl)-2-[4-((S)-tetrahydrofuran-3-yloxy)-benzyl]-benzene, a method for its preparation and the use thereof for preparing medicaments |
15 Apr, 2027
(2 years from now)
| Active |
US8883805
(Pediatric)
| Process for the preparation of chiral 8-(3-aminopiperidin-1-yl)-xanthines |
26 May, 2026
(1 year, 5 months from now)
| Active |
US8883805 | Process for the preparation of chiral 8-(3-aminopiperidin-1-yl)-xanthines |
26 Nov, 2025
(11 months from now)
| Active |
US7407955
(Pediatric)
| 8-[3-amino-piperidin-1-yl]-xanthines, the preparation thereof and their use as pharmaceutical compositions |
02 Nov, 2025
(10 months from now)
| Active |
US7407955 | 8-[3-amino-piperidin-1-yl]-xanthines, the preparation thereof and their use as pharmaceutical compositions |
02 May, 2025
(4 months from now)
| Active |
US8119648 | 8-[3-amino-piperidin-1-yl]-xanthines, the preparation thereof and their use as pharmaceutical compositions |
12 Aug, 2023
(1 year, 4 months ago)
| Expired |
US8178541 | 8-[3-amino-piperidin-1-yl]-xanthines, the preparation thereof and their use as pharmaceutical compositions |
12 Aug, 2023
(1 year, 4 months ago)
| Expired |
US6890898 | Method of regulating glucose metabolism, and reagents related thereto |
02 Feb, 2019
(5 years ago)
| Expired |
US7078381 | Method of regulating glucose metabolism, and reagents related thereto |
02 Feb, 2019
(5 years ago)
| Expired |
US7459428 | Method of regulating glucose metabolism, and reagents related thereto |
02 Feb, 2019
(5 years ago)
| Expired |
US6303661 | Use of dipeptidyl peptidase IV effectors for lowering the blood glucose level in mammals |
24 Apr, 2017
(7 years ago)
| Expired |
Discover which of these patents contain the active ingredient(API) of the drug, their family patents, along with litigation and legal activity details of these patents on Glyxambi's drug page
8. Jardiance
Jardiance is protected by 18 patents, out of which none have expired yet. Check out its patent list below.
Drug Patent Number | Drug Patent Title | Drug Patent Expiry | Status |
---|---|---|---|
US9949998
(Pediatric)
| Pharmaceutical composition, methods for treating and uses thereof |
11 Dec, 2034
(9 years from now)
| Active |
US9949997
(Pediatric)
| Pharmaceutical composition, methods for treating and uses thereof |
17 Nov, 2034
(9 years from now)
| Active |
US10258637
(Pediatric)
| Pharmaceutical composition, methods for treating and uses thereof |
03 Oct, 2034
(9 years from now)
| Active |
US11090323
(Pediatric)
| Pharmaceutical composition, methods for treating and uses thereof |
03 Oct, 2034
(9 years from now)
| Active |
US9949998 | Pharmaceutical composition, methods for treating and uses thereof |
11 Jun, 2034
(9 years from now)
| Active |
US9949997 | Pharmaceutical composition, methods for treating and uses thereof |
17 May, 2034
(9 years from now)
| Active |
US10258637 | Pharmaceutical composition, methods for treating and uses thereof |
03 Apr, 2034
(9 years from now)
| Active |
US11090323 | Pharmaceutical composition, methods for treating and uses thereof |
03 Apr, 2034
(9 years from now)
| Active |
US11666590 | Pharmaceutical composition, methods for treating and uses thereof |
03 Apr, 2034
(9 years from now)
| Active |
US11813275 | Pharmaceutical composition, methods for treating and uses thereof |
03 Apr, 2034
(9 years from now)
| Active |
US11833166 | Pharmaceutical composition, methods for treating and uses thereof |
03 Apr, 2034
(9 years from now)
| Active |
US10406172 | Pharmaceutical composition, methods for treating and uses thereof |
15 Jun, 2030
(5 years from now)
| Active |
US8551957
(Pediatric)
| Pharmaceutical composition comprising a glucopyranosyl-substituted benzene derivate |
14 Apr, 2030
(5 years from now)
| Active |
US8551957 | Pharmaceutical composition comprising a glucopyranosyl-substituted benzene derivate |
14 Oct, 2029
(4 years from now)
| Active |
US7579449
(Pediatric)
| Glucopyranosyl-substituted phenyl derivatives, medicaments containing such compounds, their use and process for their manufacture |
01 Feb, 2029
(4 years from now)
| Active |
US7579449 | Glucopyranosyl-substituted phenyl derivatives, medicaments containing such compounds, their use and process for their manufacture |
01 Aug, 2028
(3 years from now)
| Active |
US7713938
(Pediatric)
| Crystalline form of 1-chloro-4-(β-D-glucopyranos-1-yl)-2-[4-((S)-tetrahydrofuran-3-yloxy)-benzyl]-benzene, a method for its preparation and the use thereof for preparing medicaments |
15 Oct, 2027
(2 years from now)
| Active |
US7713938 | Crystalline form of 1-chloro-4-(β-D-glucopyranos-1-yl)-2-[4-((S)-tetrahydrofuran-3-yloxy)-benzyl]-benzene, a method for its preparation and the use thereof for preparing medicaments |
15 Apr, 2027
(2 years from now)
| Active |
Discover which of these patents contain the active ingredient(API) of the drug, their family patents, along with litigation and legal activity details of these patents on Jardiance's drug page
9. Jentadueto
Jentadueto is protected by 24 patents, out of which 6 have expired. Check out its patent list below.
Drug Patent Number | Drug Patent Title | Drug Patent Expiry | Status |
---|---|---|---|
US8846695
(Pediatric)
| Treatment for diabetes in patients with inadequate glycemic control despite metformin therapy comprising a DPP-IV inhibitor |
04 Dec, 2030
(5 years from now)
| Active |
US9155705
(Pediatric)
| DPP-IV inhibitor combined with a further antidiabetic agent, tablets comprising such formulations, their use and process for their preparation |
21 Nov, 2030
(5 years from now)
| Active |
US8846695 | Treatment for diabetes in patients with inadequate glycemic control despite metformin therapy comprising a DPP-IV inhibitor |
04 Jun, 2030
(5 years from now)
| Active |
US9155705 | DPP-IV inhibitor combined with a further antidiabetic agent, tablets comprising such formulations, their use and process for their preparation |
21 May, 2030
(5 years from now)
| Active |
US11911388 | Treatment for diabetes in patients with insufficient glycemic control despite therapy with an oral or non-oral antidiabetic drug |
10 Apr, 2030
(5 years from now)
| Active |
US10022379
(Pediatric)
| DPP-IV inhibitor combined with a further antidiabetic agent, tablets comprising such formulations, their use and process for their preparation |
02 Oct, 2029
(4 years from now)
| Active |
US10973827
(Pediatric)
| DPP-IV inhibitor combined with a further antidiabetic agent, tablets comprising such formulations, their use and process for their preparation |
02 Oct, 2029
(4 years from now)
| Active |
US9415016
(Pediatric)
| DPP-IV inhibitor combined with a further antidiabetic agent, tablets comprising such formulations, their use and process for their preparation |
02 Oct, 2029
(4 years from now)
| Active |
US10022379 | DPP-IV inhibitor combined with a further antidiabetic agent, tablets comprising such formulations, their use and process for their preparation |
02 Apr, 2029
(4 years from now)
| Active |
US10973827 | DPP-IV inhibitor combined with a further antidiabetic agent, tablets comprising such formulations, their use and process for their preparation |
02 Apr, 2029
(4 years from now)
| Active |
US9415016 | DPP-IV inhibitor combined with a further antidiabetic agent, tablets comprising such formulations, their use and process for their preparation |
02 Apr, 2029
(4 years from now)
| Active |
US8673927
(Pediatric)
| Uses of DPP-IV inhibitors |
04 Nov, 2027
(2 years from now)
| Active |
US8673927 | Uses of DPP-IV inhibitors |
04 May, 2027
(2 years from now)
| Active |
US9173859 | Uses of DPP IV inhibitors |
04 May, 2027
(2 years from now)
| Active |
US8883805
(Pediatric)
| Process for the preparation of chiral 8-(3-aminopiperidin-1-yl)-xanthines |
26 May, 2026
(1 year, 5 months from now)
| Active |
US8883805 | Process for the preparation of chiral 8-(3-aminopiperidin-1-yl)-xanthines |
26 Nov, 2025
(11 months from now)
| Active |
US7407955
(Pediatric)
| 8-[3-amino-piperidin-1-yl]-xanthines, the preparation thereof and their use as pharmaceutical compositions |
02 Nov, 2025
(10 months from now)
| Active |
US7407955 | 8-[3-amino-piperidin-1-yl]-xanthines, the preparation thereof and their use as pharmaceutical compositions |
02 May, 2025
(4 months from now)
| Active |
US8119648 | 8-[3-amino-piperidin-1-yl]-xanthines, the preparation thereof and their use as pharmaceutical compositions |
12 Aug, 2023
(1 year, 4 months ago)
| Expired |
US8178541 | 8-[3-amino-piperidin-1-yl]-xanthines, the preparation thereof and their use as pharmaceutical compositions |
12 Aug, 2023
(1 year, 4 months ago)
| Expired |
US6890898 | Method of regulating glucose metabolism, and reagents related thereto |
02 Feb, 2019
(5 years ago)
| Expired |
US7078381 | Method of regulating glucose metabolism, and reagents related thereto |
02 Feb, 2019
(5 years ago)
| Expired |
US7459428 | Method of regulating glucose metabolism, and reagents related thereto |
02 Feb, 2019
(5 years ago)
| Expired |
US6303661 | Use of dipeptidyl peptidase IV effectors for lowering the blood glucose level in mammals |
24 Apr, 2017
(7 years ago)
| Expired |
Discover which of these patents contain the active ingredient(API) of the drug, their family patents, along with litigation and legal activity details of these patents on Jentadueto's drug page
10. Jentadueto Xr
Jentadueto Xr is protected by 27 patents, out of which 9 have expired. Check out its patent list below.
Drug Patent Number | Drug Patent Title | Drug Patent Expiry | Status |
---|---|---|---|
US9555001
(Pediatric)
| Pharmaceutical composition and uses thereof |
06 Sep, 2033
(8 years from now)
| Active |
US9555001 | Pharmaceutical composition and uses thereof |
06 Mar, 2033
(8 years from now)
| Active |
US9155705
(Pediatric)
| DPP-IV inhibitor combined with a further antidiabetic agent, tablets comprising such formulations, their use and process for their preparation |
21 Nov, 2030
(5 years from now)
| Active |
US8846695 | Treatment for diabetes in patients with inadequate glycemic control despite metformin therapy comprising a DPP-IV inhibitor |
04 Jun, 2030
(5 years from now)
| Active |
US9155705 | DPP-IV inhibitor combined with a further antidiabetic agent, tablets comprising such formulations, their use and process for their preparation |
21 May, 2030
(5 years from now)
| Active |
US11911388 | Treatment for diabetes in patients with insufficient glycemic control despite therapy with an oral or non-oral antidiabetic drug |
10 Apr, 2030
(5 years from now)
| Active |
US10022379
(Pediatric)
| DPP-IV inhibitor combined with a further antidiabetic agent, tablets comprising such formulations, their use and process for their preparation |
02 Oct, 2029
(4 years from now)
| Active |
US9415016
(Pediatric)
| DPP-IV inhibitor combined with a further antidiabetic agent, tablets comprising such formulations, their use and process for their preparation |
02 Oct, 2029
(4 years from now)
| Active |
US10022379 | DPP-IV inhibitor combined with a further antidiabetic agent, tablets comprising such formulations, their use and process for their preparation |
02 Apr, 2029
(4 years from now)
| Active |
US9415016 | DPP-IV inhibitor combined with a further antidiabetic agent, tablets comprising such formulations, their use and process for their preparation |
02 Apr, 2029
(4 years from now)
| Active |
US8673927
(Pediatric)
| Uses of DPP-IV inhibitors |
04 Nov, 2027
(2 years from now)
| Active |
US9173859
(Pediatric)
| Uses of DPP IV inhibitors |
04 Nov, 2027
(2 years from now)
| Active |
US8673927 | Uses of DPP-IV inhibitors |
04 May, 2027
(2 years from now)
| Active |
US9173859 | Uses of DPP IV inhibitors |
04 May, 2027
(2 years from now)
| Active |
US8883805
(Pediatric)
| Process for the preparation of chiral 8-(3-aminopiperidin-1-yl)-xanthines |
26 May, 2026
(1 year, 5 months from now)
| Active |
US8883805 | Process for the preparation of chiral 8-(3-aminopiperidin-1-yl)-xanthines |
26 Nov, 2025
(11 months from now)
| Active |
US7407955
(Pediatric)
| 8-[3-amino-piperidin-1-yl]-xanthines, the preparation thereof and their use as pharmaceutical compositions |
02 Nov, 2025
(10 months from now)
| Active |
US7407955 | 8-[3-amino-piperidin-1-yl]-xanthines, the preparation thereof and their use as pharmaceutical compositions |
02 May, 2025
(4 months from now)
| Active |
US8119648 | 8-[3-amino-piperidin-1-yl]-xanthines, the preparation thereof and their use as pharmaceutical compositions |
12 Aug, 2023
(1 year, 4 months ago)
| Expired |
US8178541 | 8-[3-amino-piperidin-1-yl]-xanthines, the preparation thereof and their use as pharmaceutical compositions |
12 Aug, 2023
(1 year, 4 months ago)
| Expired |
US6488962 | Tablet shapes to enhance gastric retention of swellable controlled-release oral dosage forms |
20 Jun, 2020
(4 years ago)
| Expired |
US6890898 | Method of regulating glucose metabolism, and reagents related thereto |
02 Feb, 2019
(5 years ago)
| Expired |
US7078381 | Method of regulating glucose metabolism, and reagents related thereto |
02 Feb, 2019
(5 years ago)
| Expired |
US7459428 | Method of regulating glucose metabolism, and reagents related thereto |
02 Feb, 2019
(5 years ago)
| Expired |
US6303661 | Use of dipeptidyl peptidase IV effectors for lowering the blood glucose level in mammals |
24 Apr, 2017
(7 years ago)
| Expired |
US6340475 | Extending the duration of drug release within the stomach during the fed mode |
19 Sep, 2016
(8 years ago)
| Expired |
US6635280 | Extending the duration of drug release within the stomach during the fed mode |
19 Sep, 2016
(8 years ago)
| Expired |
Discover which of these patents contain the active ingredient(API) of the drug, their family patents, along with litigation and legal activity details of these patents on Jentadueto Xr's drug page
11. Micardis
Micardis is protected by 4 patents, out of which all have expired. Check out its patent list below.
Drug Patent Number | Drug Patent Title | Drug Patent Expiry | Status |
---|---|---|---|
US8003679 | Use of inhibitors of the renin-angiotensin system |
06 Oct, 2022
(2 years ago)
| Expired |
US7998953 | Use of inhibitors of the renin-angiotensin system |
06 Jun, 2020
(4 years ago)
| Expired |
US6358986 | Polymorphs of telmisartan |
10 Jan, 2020
(4 years ago)
| Expired |
US5591762 | Benzimidazoles useful as angiotensin-11 antagonists |
07 Jan, 2014
(10 years ago)
| Expired |
Discover which of these patents contain the active ingredient(API) of the drug, their family patents, along with litigation and legal activity details of these patents on Micardis's drug page
12. Micardis Hct
Micardis Hct is protected by 2 patents, out of which all have expired. Check out its patent list below.
Drug Patent Number | Drug Patent Title | Drug Patent Expiry | Status |
---|---|---|---|
US6358986 | Polymorphs of telmisartan |
10 Jan, 2020
(4 years ago)
| Expired |
US5591762 | Benzimidazoles useful as angiotensin-11 antagonists |
07 Jan, 2014
(10 years ago)
| Expired |
Discover which of these patents contain the active ingredient(API) of the drug, their family patents, along with litigation and legal activity details of these patents on Micardis Hct's drug page
13. Mirapex
Mirapex is protected by 2 patents, out of which all have expired. Check out its patent list below.
Drug Patent Number | Drug Patent Title | Drug Patent Expiry | Status |
---|---|---|---|
US6001861 | Use of pramipexole in the treatment of restless legs syndrome |
16 Jan, 2018
(6 years ago)
| Expired |
US6194445 | Use of pramipexole in the treatment of restless legs syndrome |
16 Jan, 2018
(6 years ago)
| Expired |
Discover which of these patents contain the active ingredient(API) of the drug, their family patents, along with litigation and legal activity details of these patents on Mirapex's drug page
14. Mirapex Er
Mirapex Er is protected by 2 patents, out of which none have expired yet. Check out its patent list below.
Drug Patent Number | Drug Patent Title | Drug Patent Expiry | Status |
---|---|---|---|
US8679533 | Pramipexole once-daily dosage form |
08 Sep, 2029
(4 years from now)
| Active |
US7695734 | Extended release tablet formulation containing pramipexole or a pharmaceutically acceptable salt thereof |
26 Apr, 2028
(3 years from now)
| Active |
Discover which of these patents contain the active ingredient(API) of the drug, their family patents, along with litigation and legal activity details of these patents on Mirapex Er's drug page
15. Ofev
Ofev is protected by 10 patents, out of which 2 have expired. Check out its patent list below.
Drug Patent Number | Drug Patent Title | Drug Patent Expiry | Status |
---|---|---|---|
US9907756
(Pediatric)
| Capsule pharmaceutical dosage form comprising a suspension formulation of an indolinone derivative |
07 Dec, 2029
(4 years from now)
| Active |
US10105323
(Pediatric)
| Pharmaceutical dosage form for immediate release of an indolinone derivative |
04 Dec, 2029
(4 years from now)
| Active |
US9907756 | Capsule pharmaceutical dosage form comprising a suspension formulation of an indolinone derivative |
07 Jun, 2029
(4 years from now)
| Active |
US10105323 | Pharmaceutical dosage form for immediate release of an indolinone derivative |
04 Jun, 2029
(4 years from now)
| Active |
US10154990
(Pediatric)
| Medicaments for the treatment or prevention of fibrotic diseases |
08 Jul, 2026
(1 year, 6 months from now)
| Active |
US6762180
(Pediatric)
| Substituted indolines which inhibit receptor tyrosine kinases |
01 Apr, 2026
(1 year, 3 months from now)
| Active |
US10154990 | Medicaments for the treatment or prevention of fibrotic diseases |
08 Jan, 2026
(1 year, 20 days from now)
| Active |
US6762180 | Substituted indolines which inhibit receptor tyrosine kinases |
01 Oct, 2025
(9 months from now)
| Active |
US7989474 | Use of Lck inhibitors for treatment of immunologic diseases |
06 Apr, 2024
(8 months ago)
| Expired |
US7119093 | 3-Z-[1-(4-(N-((4-Methyl-piperazin-1-yl)-methylcarbonyl)-N-methyl-amino)-anilino)-1-phenyl-methylene]-6-methoxycarbonyl-2-indolinone-monoethanesulphonate and the use thereof as a pharmaceutical composition |
21 Feb, 2024
(9 months ago)
| Expired |
Discover which of these patents contain the active ingredient(API) of the drug, their family patents, along with litigation and legal activity details of these patents on Ofev's drug page
16. Pradaxa
Pradaxa is protected by 11 patents, out of which 5 have expired. Check out its patent list below.
Drug Patent Number | Drug Patent Title | Drug Patent Expiry | Status |
---|---|---|---|
US9034822
(Pediatric)
| Methods of using antibodies during anticoagulant therapy of dabigatran and/or related compounds |
20 Jul, 2031
(6 years from now)
| Active |
US9034822 | Methods of using antibodies during anticoagulant therapy of dabigatran and/or related compounds |
20 Jan, 2031
(6 years from now)
| Active |
US7866474
(Pediatric)
| Film container |
02 Mar, 2028
(3 years from now)
| Active |
US7866474 | Film container |
31 Aug, 2027
(2 years from now)
| Active |
US7932273
(Pediatric)
| 3-[(2-{[4-(hexyloxycarbonylaminoiminomethyl) phenylamino]methyl}-1-methyl-1H-benzimidazol-5-carbonyl)pyridin-2-ylamino]propionic acid ethylester methansulfonate and its use as a medicament |
07 Mar, 2026
(1 year, 2 months from now)
| Active |
US7932273 | 3-[(2-{[4-(hexyloxycarbonylaminoiminomethyl) phenylamino]methyl}-1-methyl-1H-benzimidazol-5-carbonyl)pyridin-2-ylamino]propionic acid ethylester methansulfonate and its use as a medicament |
07 Sep, 2025
(8 months from now)
| Active |
US9925174
(Pediatric)
| Administration form for the oral application of 3-[(2-{[4-(hexyloxycarbonyl-amino-imino-methyl)-phenylamino]-methyl}-1-methyl-1 H-benzimidazol acid ethyl ester and the salts thereof |
14 Dec, 2023
(1 year, 5 days ago)
| Expired |
US9925174 | Administration form for the oral application of 3-[(2-{[4-(hexyloxycarbonyl-amino-imino-methyl)-phenylamino]-methyl}-1-methyl-1 H-benzimidazol acid ethyl ester and the salts thereof |
14 Jun, 2023
(1 year, 6 months ago)
| Expired |
US6087380
(Pediatric)
| Disubstituted bicyclic heterocycles, the preparations and the use thereof as pharmaceutical compositions |
28 Jun, 2022
(2 years ago)
| Expired |
US6087380 | Disubstituted bicyclic heterocycles, the preparations and the use thereof as pharmaceutical compositions |
28 Dec, 2021
(2 years ago)
| Expired |
US6087380 | Disubstituted bicyclic heterocycles, the preparations and the use thereof as pharmaceutical compositions |
18 Feb, 2018
(6 years ago)
| Expired |
Discover which of these patents contain the active ingredient(API) of the drug, their family patents, along with litigation and legal activity details of these patents on Pradaxa's drug page
17. Spiriva
Spiriva is protected by 20 patents, out of which 15 have expired. Check out its patent list below.
Drug Patent Number | Drug Patent Title | Drug Patent Expiry | Status |
---|---|---|---|
US9010323 | Inhaler and sieve for an inhaler |
19 Apr, 2030
(5 years from now)
| Active |
US7694676
(Pediatric)
| Dry powder inhaler |
12 Sep, 2027
(2 years from now)
| Active |
US7694676 | Dry powder inhaler |
12 Mar, 2027
(2 years from now)
| Active |
US8022082
(Pediatric)
| Method for the administration of an anticholinergic by inhalation |
19 Jul, 2026
(1 year, 6 months from now)
| Active |
US8022082 | Method for the administration of an anticholinergic by inhalation |
19 Jan, 2026
(1 year, 1 month from now)
| Active |
US7070800
(Pediatric)
| Inhalable powder containing tiotropium |
22 Jul, 2022
(2 years ago)
| Expired |
USRE38912
(Pediatric)
| Process for preparing powder formulations |
11 Apr, 2022
(2 years ago)
| Expired |
US6777423
(Pediatric)
| Crystalline tiotropium bromide monohydrate, processes for the preparation thereof, and pharmaceutical compositions |
24 Mar, 2022
(2 years ago)
| Expired |
US6908928
(Pediatric)
| Crystalline tiotropium bromide monohydrate, processes for the preparation thereof, and pharmaceutical compositions |
24 Mar, 2022
(2 years ago)
| Expired |
US7309707
(Pediatric)
| Crystalline micronisate, process for the manufacture thereof and use thereof for the preparation of a medicament |
24 Mar, 2022
(2 years ago)
| Expired |
US7642268
(Pediatric)
| Crystalline micronisate, process for the manufacture thereof and use thereof for the preparation of a medicament |
24 Mar, 2022
(2 years ago)
| Expired |
US7070800 | Inhalable powder containing tiotropium |
22 Jan, 2022
(2 years ago)
| Expired |
USRE38912 | Process for preparing powder formulations |
11 Oct, 2021
(3 years ago)
| Expired |
US6777423 | Crystalline tiotropium bromide monohydrate, processes for the preparation thereof, and pharmaceutical compositions |
24 Sep, 2021
(3 years ago)
| Expired |
US6908928 | Crystalline tiotropium bromide monohydrate, processes for the preparation thereof, and pharmaceutical compositions |
24 Sep, 2021
(3 years ago)
| Expired |
US7309707 | Crystalline micronisate, process for the manufacture thereof and use thereof for the preparation of a medicament |
24 Sep, 2021
(3 years ago)
| Expired |
US7642268 | Crystalline micronisate, process for the manufacture thereof and use thereof for the preparation of a medicament |
24 Sep, 2021
(3 years ago)
| Expired |
USRE39820
(Pediatric)
| Esters of thienyl carboxylic acids and amino alcohols and their quaternization products |
30 Jul, 2018
(6 years ago)
| Expired |
USRE39820 | Esters of thienyl carboxylic acids and amino alcohols and their quaternization products |
30 Jan, 2018
(6 years ago)
| Expired |
US5478578 | Powders for inhalation |
26 Dec, 2012
(11 years ago)
| Expired |
Discover which of these patents contain the active ingredient(API) of the drug, their family patents, along with litigation and legal activity details of these patents on Spiriva's drug page
18. Spiriva Respimat
Spiriva Respimat is protected by 39 patents, out of which 28 have expired. Check out its patent list below.
Drug Patent Number | Drug Patent Title | Drug Patent Expiry | Status |
---|---|---|---|
US8733341
(Pediatric)
| Atomizer and method of atomizing fluid with a nozzle rinsing mechanism |
16 Apr, 2031
(6 years from now)
| Active |
US8733341 | Atomizer and method of atomizing fluid with a nozzle rinsing mechanism |
16 Oct, 2030
(5 years from now)
| Active |
US7837235
(Pediatric)
| Device for clamping a fluidic component |
13 Sep, 2028
(3 years from now)
| Active |
US7837235 | Device for clamping a fluidic component |
13 Mar, 2028
(3 years from now)
| Active |
US9027967
(Pediatric)
| Device for clamping a fluidic component |
30 Sep, 2027
(2 years from now)
| Active |
US7396341
(Pediatric)
| Blocking device for a locking stressing mechanism having a spring-actuated output drive device |
10 Apr, 2027
(2 years from now)
| Active |
US9027967 | Device for clamping a fluidic component |
31 Mar, 2027
(2 years from now)
| Active |
US7396341 | Blocking device for a locking stressing mechanism having a spring-actuated output drive device |
10 Oct, 2026
(1 year, 9 months from now)
| Active |
US7896264
(Pediatric)
| Microstructured high pressure nozzle with built-in filter function |
26 Nov, 2025
(11 months from now)
| Active |
US7896264 | Microstructured high pressure nozzle with built-in filter function |
26 May, 2025
(5 months from now)
| Active |
US7284474
(Pediatric)
| Piston-pumping system having o-ring seal properties |
26 Feb, 2025
(2 months from now)
| Active |
US7284474 | Piston-pumping system having o-ring seal properties |
26 Aug, 2024
(3 months ago)
| Expired |
US7988001
(Pediatric)
| Container provided with a pressure equalization opening |
04 Feb, 2022
(2 years ago)
| Expired |
US7988001 | Container provided with a pressure equalization opening |
04 Aug, 2021
(3 years ago)
| Expired |
US6988496
(Pediatric)
| Cartridge for a liquid |
23 Aug, 2020
(4 years ago)
| Expired |
US6988496 | Cartridge for a liquid |
23 Feb, 2020
(4 years ago)
| Expired |
US7802568
(Pediatric)
| Cartridge for a liquid |
26 Aug, 2019
(5 years ago)
| Expired |
US6846413
(Pediatric)
| Microstructured filter |
28 Feb, 2019
(5 years ago)
| Expired |
US6977042
(Pediatric)
| Microstructured filter |
28 Feb, 2019
(5 years ago)
| Expired |
US7802568 | Cartridge for a liquid |
26 Feb, 2019
(5 years ago)
| Expired |
US6846413 | Microstructured filter |
28 Aug, 2018
(6 years ago)
| Expired |
US6977042 | Microstructured filter |
28 Aug, 2018
(6 years ago)
| Expired |
USRE39820
(Pediatric)
| Esters of thienyl carboxylic acids and amino alcohols and their quaternization products |
30 Jul, 2018
(6 years ago)
| Expired |
USRE39820 | Esters of thienyl carboxylic acids and amino alcohols and their quaternization products |
30 Jan, 2018
(6 years ago)
| Expired |
US6149054
(Pediatric)
| Mechanical counter for a metering apparatus |
16 Jun, 2017
(7 years ago)
| Expired |
US6453795
(Pediatric)
| Locking mechanism for a spring-actuated device |
05 Jun, 2017
(7 years ago)
| Expired |
US5964416
(Pediatric)
| Device for producing high pressure in a fluid in miniature |
04 Apr, 2017
(7 years ago)
| Expired |
US6726124
(Pediatric)
| Device for producing high pressure in a fluid in miniature |
04 Apr, 2017
(7 years ago)
| Expired |
US7104470
(Pediatric)
| Device for producing high pressure in a fluid in miniature |
04 Apr, 2017
(7 years ago)
| Expired |
US6149054 | Mechanical counter for a metering apparatus |
16 Dec, 2016
(8 years ago)
| Expired |
US6453795 | Locking mechanism for a spring-actuated device |
05 Dec, 2016
(8 years ago)
| Expired |
US6176442
(Pediatric)
| Device for mounting a component exposed to a pressurized fluid |
01 Dec, 2016
(8 years ago)
| Expired |
US7246615
(Pediatric)
| Atomising nozzle and filter and spray generating device |
01 Dec, 2016
(8 years ago)
| Expired |
US5964416 | Device for producing high pressure in a fluid in miniature |
04 Oct, 2016
(8 years ago)
| Expired |
US6726124 | Device for producing high pressure in a fluid in miniature |
04 Oct, 2016
(8 years ago)
| Expired |
US7104470 | Device for producing high pressure in a fluid in miniature |
04 Oct, 2016
(8 years ago)
| Expired |
US6176242 | Method of treating manic depression by brain infusion |
31 May, 2016
(8 years ago)
| Expired |
US6176442 | Device for mounting a component exposed to a pressurized fluid |
31 May, 2016
(8 years ago)
| Expired |
US7246615 | Atomising nozzle and filter and spray generating device |
31 May, 2016
(8 years ago)
| Expired |
Discover which of these patents contain the active ingredient(API) of the drug, their family patents, along with litigation and legal activity details of these patents on Spiriva Respimat's drug page
19. Stiolto Respimat
Stiolto Respimat is protected by 34 patents, out of which 23 have expired. Check out its patent list below.
Drug Patent Number | Drug Patent Title | Drug Patent Expiry | Status |
---|---|---|---|
US8733341 | Atomizer and method of atomizing fluid with a nozzle rinsing mechanism |
16 Oct, 2030
(5 years from now)
| Active |
US7837235
(Pediatric)
| Device for clamping a fluidic component |
13 Sep, 2028
(3 years from now)
| Active |
US7837235 | Device for clamping a fluidic component |
13 Mar, 2028
(3 years from now)
| Active |
US7396341
(Pediatric)
| Blocking device for a locking stressing mechanism having a spring-actuated output drive device |
10 Apr, 2027
(2 years from now)
| Active |
US9027967 | Device for clamping a fluidic component |
31 Mar, 2027
(2 years from now)
| Active |
US7727984 | Medicaments for the treatment of chronic obstructive pulmonary disease |
19 Jan, 2027
(2 years from now)
| Active |
US7396341 | Blocking device for a locking stressing mechanism having a spring-actuated output drive device |
10 Oct, 2026
(1 year, 9 months from now)
| Active |
US7896264 | Microstructured high pressure nozzle with built-in filter function |
26 May, 2025
(5 months from now)
| Active |
US7220742 | Enantiomerically pure beta agonists, process for the manufacture thereof and use thereof as medicaments |
12 May, 2025
(4 months from now)
| Active |
US8034809 | Enantiomerically pure beta agonists, process for the manufacture thereof and use thereof as medicaments |
12 May, 2025
(4 months from now)
| Active |
US7284474
(Pediatric)
| Piston-pumping system having o-ring seal properties |
26 Feb, 2025
(2 months from now)
| Active |
US7284474 | Piston-pumping system having o-ring seal properties |
26 Aug, 2024
(3 months ago)
| Expired |
US7056916 | Medicaments for the treatment of chronic obstructive pulmonary disease |
07 Dec, 2023
(1 year, 12 days ago)
| Expired |
US7491719 | Enantiomerically pure beta agonists, process for the manufacture thereof, and use thereof as medicaments |
10 Nov, 2023
(1 year, 1 month ago)
| Expired |
US7786111 | Medicaments for the treatment of chronic obstructive pulmonary disease |
10 Nov, 2023
(1 year, 1 month ago)
| Expired |
US8044046 | Medicaments for the treatment of chronic obstructive pulmonary disease |
10 Nov, 2023
(1 year, 1 month ago)
| Expired |
US7988001 | Container provided with a pressure equalization opening |
04 Aug, 2021
(3 years ago)
| Expired |
US6988496
(Pediatric)
| Cartridge for a liquid |
23 Aug, 2020
(4 years ago)
| Expired |
US6988496 | Cartridge for a liquid |
23 Feb, 2020
(4 years ago)
| Expired |
US7802568
(Pediatric)
| Cartridge for a liquid |
26 Aug, 2019
(5 years ago)
| Expired |
US6846413
(Pediatric)
| Microstructured filter |
28 Feb, 2019
(5 years ago)
| Expired |
US6977042
(Pediatric)
| Microstructured filter |
28 Feb, 2019
(5 years ago)
| Expired |
US7802568 | Cartridge for a liquid |
26 Feb, 2019
(5 years ago)
| Expired |
US6846413 | Microstructured filter |
28 Aug, 2018
(6 years ago)
| Expired |
US6977042 | Microstructured filter |
28 Aug, 2018
(6 years ago)
| Expired |
USRE39820 | Esters of thienyl carboxylic acids and amino alcohols and their quaternization products |
30 Jan, 2018
(6 years ago)
| Expired |
US6149054
(Pediatric)
| Mechanical counter for a metering apparatus |
19 Jun, 2017
(7 years ago)
| Expired |
US6149054 | Mechanical counter for a metering apparatus |
19 Dec, 2016
(8 years ago)
| Expired |
US6453795 | Locking mechanism for a spring-actuated device |
05 Dec, 2016
(8 years ago)
| Expired |
US5964416 | Device for producing high pressure in a fluid in miniature |
04 Oct, 2016
(8 years ago)
| Expired |
US6176442 | Device for mounting a component exposed to a pressurized fluid |
04 Oct, 2016
(8 years ago)
| Expired |
US6726124 | Device for producing high pressure in a fluid in miniature |
04 Oct, 2016
(8 years ago)
| Expired |
US7104470 | Device for producing high pressure in a fluid in miniature |
04 Oct, 2016
(8 years ago)
| Expired |
US7246615 | Atomising nozzle and filter and spray generating device |
31 May, 2016
(8 years ago)
| Expired |
Discover which of these patents contain the active ingredient(API) of the drug, their family patents, along with litigation and legal activity details of these patents on Stiolto Respimat's drug page
20. Striverdi Respimat
Striverdi Respimat is protected by 25 patents, out of which 17 have expired. Check out its patent list below.
Drug Patent Number | Drug Patent Title | Drug Patent Expiry | Status |
---|---|---|---|
US8733341 | Atomizer and method of atomizing fluid with a nozzle rinsing mechanism |
16 Oct, 2030
(5 years from now)
| Active |
US7837235 | Device for clamping a fluidic component |
13 Mar, 2028
(3 years from now)
| Active |
US9027967 | Device for clamping a fluidic component |
31 Mar, 2027
(2 years from now)
| Active |
US7727984 | Medicaments for the treatment of chronic obstructive pulmonary disease |
19 Jan, 2027
(2 years from now)
| Active |
US7396341 | Blocking device for a locking stressing mechanism having a spring-actuated output drive device |
10 Oct, 2026
(1 year, 9 months from now)
| Active |
US7896264 | Microstructured high pressure nozzle with built-in filter function |
26 May, 2025
(5 months from now)
| Active |
US7220742 | Enantiomerically pure beta agonists, process for the manufacture thereof and use thereof as medicaments |
12 May, 2025
(4 months from now)
| Active |
US8034809 | Enantiomerically pure beta agonists, process for the manufacture thereof and use thereof as medicaments |
12 May, 2025
(4 months from now)
| Active |
US7284474 | Piston-pumping system having o-ring seal properties |
26 Aug, 2024
(3 months ago)
| Expired |
US7056916 | Medicaments for the treatment of chronic obstructive pulmonary disease |
07 Dec, 2023
(1 year, 12 days ago)
| Expired |
US7491719 | Enantiomerically pure beta agonists, process for the manufacture thereof, and use thereof as medicaments |
10 Nov, 2023
(1 year, 1 month ago)
| Expired |
US7786111 | Medicaments for the treatment of chronic obstructive pulmonary disease |
10 Nov, 2023
(1 year, 1 month ago)
| Expired |
US8044046 | Medicaments for the treatment of chronic obstructive pulmonary disease |
10 Nov, 2023
(1 year, 1 month ago)
| Expired |
US7988001 | Container provided with a pressure equalization opening |
04 Aug, 2021
(3 years ago)
| Expired |
US6988496 | Cartridge for a liquid |
23 Feb, 2020
(4 years ago)
| Expired |
US7802568 | Cartridge for a liquid |
26 Feb, 2019
(5 years ago)
| Expired |
US6846413 | Microstructured filter |
28 Aug, 2018
(6 years ago)
| Expired |
US6977042 | Microstructured filter |
28 Aug, 2018
(6 years ago)
| Expired |
US6149054 | Mechanical counter for a metering apparatus |
19 Dec, 2016
(8 years ago)
| Expired |
US6453795 | Locking mechanism for a spring-actuated device |
05 Dec, 2016
(8 years ago)
| Expired |
US5964416 | Device for producing high pressure in a fluid in miniature |
04 Oct, 2016
(8 years ago)
| Expired |
US6176442 | Device for mounting a component exposed to a pressurized fluid |
04 Oct, 2016
(8 years ago)
| Expired |
US6726124 | Device for producing high pressure in a fluid in miniature |
04 Oct, 2016
(8 years ago)
| Expired |
US7104470 | Device for producing high pressure in a fluid in miniature |
04 Oct, 2016
(8 years ago)
| Expired |
US7246615 | Atomising nozzle and filter and spray generating device |
31 May, 2016
(8 years ago)
| Expired |
Discover which of these patents contain the active ingredient(API) of the drug, their family patents, along with litigation and legal activity details of these patents on Striverdi Respimat's drug page
21. Synjardy
Synjardy is protected by 14 patents, out of which none have expired yet. Check out its patent list below.
Drug Patent Number | Drug Patent Title | Drug Patent Expiry | Status |
---|---|---|---|
US9949997
(Pediatric)
| Pharmaceutical composition, methods for treating and uses thereof |
17 Nov, 2034
(9 years from now)
| Active |
US10258637
(Pediatric)
| Pharmaceutical composition, methods for treating and uses thereof |
03 Oct, 2034
(9 years from now)
| Active |
US11090323
(Pediatric)
| Pharmaceutical composition, methods for treating and uses thereof |
03 Oct, 2034
(9 years from now)
| Active |
US9949997 | Pharmaceutical composition, methods for treating and uses thereof |
17 May, 2034
(9 years from now)
| Active |
US10258637 | Pharmaceutical composition, methods for treating and uses thereof |
03 Apr, 2034
(9 years from now)
| Active |
US11090323 | Pharmaceutical composition, methods for treating and uses thereof |
03 Apr, 2034
(9 years from now)
| Active |
US11813275 | Pharmaceutical composition, methods for treating and uses thereof |
03 Apr, 2034
(9 years from now)
| Active |
US11833166 | Pharmaceutical composition, methods for treating and uses thereof |
03 Apr, 2034
(9 years from now)
| Active |
US10610489
(Pediatric)
| Pharmaceutical composition, pharmaceutical dosage form, process for their preparation, methods for treating and uses thereof |
30 Mar, 2031
(6 years from now)
| Active |
US10610489 | Pharmaceutical composition, pharmaceutical dosage form, process for their preparation, methods for treating and uses thereof |
30 Sep, 2030
(5 years from now)
| Active |
US7579449
(Pediatric)
| Glucopyranosyl-substituted phenyl derivatives, medicaments containing such compounds, their use and process for their manufacture |
01 Feb, 2029
(4 years from now)
| Active |
US7579449 | Glucopyranosyl-substituted phenyl derivatives, medicaments containing such compounds, their use and process for their manufacture |
01 Aug, 2028
(3 years from now)
| Active |
US7713938
(Pediatric)
| Crystalline form of 1-chloro-4-(β-D-glucopyranos-1-yl)-2-[4-((S)-tetrahydrofuran-3-yloxy)-benzyl]-benzene, a method for its preparation and the use thereof for preparing medicaments |
15 Oct, 2027
(2 years from now)
| Active |
US7713938 | Crystalline form of 1-chloro-4-(β-D-glucopyranos-1-yl)-2-[4-((S)-tetrahydrofuran-3-yloxy)-benzyl]-benzene, a method for its preparation and the use thereof for preparing medicaments |
15 Apr, 2027
(2 years from now)
| Active |
Discover which of these patents contain the active ingredient(API) of the drug, their family patents, along with litigation and legal activity details of these patents on Synjardy's drug page
22. Synjardy Xr
Synjardy Xr is protected by 17 patents, out of which 1 has expired. Check out its patent list below.
Drug Patent Number | Drug Patent Title | Drug Patent Expiry | Status |
---|---|---|---|
US9949998
(Pediatric)
| Pharmaceutical composition, methods for treating and uses thereof |
11 Dec, 2034
(9 years from now)
| Active |
US9949997
(Pediatric)
| Pharmaceutical composition, methods for treating and uses thereof |
17 Nov, 2034
(9 years from now)
| Active |
US10258637
(Pediatric)
| Pharmaceutical composition, methods for treating and uses thereof |
03 Oct, 2034
(9 years from now)
| Active |
US11090323
(Pediatric)
| Pharmaceutical composition, methods for treating and uses thereof |
03 Oct, 2034
(9 years from now)
| Active |
US9949998 | Pharmaceutical composition, methods for treating and uses thereof |
11 Jun, 2034
(9 years from now)
| Active |
US9949997 | Pharmaceutical composition, methods for treating and uses thereof |
17 May, 2034
(9 years from now)
| Active |
US10258637 | Pharmaceutical composition, methods for treating and uses thereof |
03 Apr, 2034
(9 years from now)
| Active |
US11090323 | Pharmaceutical composition, methods for treating and uses thereof |
03 Apr, 2034
(9 years from now)
| Active |
US11813275 | Pharmaceutical composition, methods for treating and uses thereof |
03 Apr, 2034
(9 years from now)
| Active |
US11833166 | Pharmaceutical composition, methods for treating and uses thereof |
03 Apr, 2034
(9 years from now)
| Active |
US10596120
(Pediatric)
| Pharmaceutical compositions |
07 Sep, 2032
(7 years from now)
| Active |
US10596120 | Pharmaceutical compositions |
07 Mar, 2032
(7 years from now)
| Active |
US7579449
(Pediatric)
| Glucopyranosyl-substituted phenyl derivatives, medicaments containing such compounds, their use and process for their manufacture |
01 Feb, 2029
(4 years from now)
| Active |
US7579449 | Glucopyranosyl-substituted phenyl derivatives, medicaments containing such compounds, their use and process for their manufacture |
01 Aug, 2028
(3 years from now)
| Active |
US7713938
(Pediatric)
| Crystalline form of 1-chloro-4-(β-D-glucopyranos-1-yl)-2-[4-((S)-tetrahydrofuran-3-yloxy)-benzyl]-benzene, a method for its preparation and the use thereof for preparing medicaments |
15 Oct, 2027
(2 years from now)
| Active |
US7713938 | Crystalline form of 1-chloro-4-(β-D-glucopyranos-1-yl)-2-[4-((S)-tetrahydrofuran-3-yloxy)-benzyl]-benzene, a method for its preparation and the use thereof for preparing medicaments |
15 Apr, 2027
(2 years from now)
| Active |
US6488962 | Tablet shapes to enhance gastric retention of swellable controlled-release oral dosage forms |
20 Jun, 2020
(4 years ago)
| Expired |
Discover which of these patents contain the active ingredient(API) of the drug, their family patents, along with litigation and legal activity details of these patents on Synjardy Xr's drug page
23. Tradjenta
Tradjenta is protected by 24 patents, out of which 6 have expired. Check out its patent list below.
Drug Patent Number | Drug Patent Title | Drug Patent Expiry | Status |
---|---|---|---|
US8853156
(Pediatric)
| Treatment for diabetes in patients inappropriate for metformin therapy |
05 Sep, 2031
(6 years from now)
| Active |
US8853156 | Treatment for diabetes in patients inappropriate for metformin therapy |
05 Mar, 2031
(6 years from now)
| Active |
US8846695
(Pediatric)
| Treatment for diabetes in patients with inadequate glycemic control despite metformin therapy comprising a DPP-IV inhibitor |
04 Dec, 2030
(5 years from now)
| Active |
US8846695 | Treatment for diabetes in patients with inadequate glycemic control despite metformin therapy comprising a DPP-IV inhibitor |
04 Jun, 2030
(5 years from now)
| Active |
US11911388 | Treatment for diabetes in patients with insufficient glycemic control despite therapy with an oral or non-oral antidiabetic drug |
10 Apr, 2030
(5 years from now)
| Active |
US10034877
(Pediatric)
| Treatment for diabetes in patients inappropriate for metformin therapy |
05 Feb, 2030
(5 years from now)
| Active |
US9486526
(Pediatric)
| Treatment for diabetes in patients inappropriate for metformin therapy |
05 Feb, 2030
(5 years from now)
| Active |
US10034877 | Treatment for diabetes in patients inappropriate for metformin therapy |
05 Aug, 2029
(4 years from now)
| Active |
US9486526 | Treatment for diabetes in patients inappropriate for metformin therapy |
05 Aug, 2029
(4 years from now)
| Active |
US11033552
(Pediatric)
| DPP IV inhibitor formulations |
04 Nov, 2027
(2 years from now)
| Active |
US8673927
(Pediatric)
| Uses of DPP-IV inhibitors |
04 Nov, 2027
(2 years from now)
| Active |
US11033552 | DPP IV inhibitor formulations |
04 May, 2027
(2 years from now)
| Active |
US8673927 | Uses of DPP-IV inhibitors |
04 May, 2027
(2 years from now)
| Active |
US9173859 | Uses of DPP IV inhibitors |
04 May, 2027
(2 years from now)
| Active |
US8883805
(Pediatric)
| Process for the preparation of chiral 8-(3-aminopiperidin-1-yl)-xanthines |
26 May, 2026
(1 year, 5 months from now)
| Active |
US8883805 | Process for the preparation of chiral 8-(3-aminopiperidin-1-yl)-xanthines |
26 Nov, 2025
(11 months from now)
| Active |
US7407955
(Pediatric)
| 8-[3-amino-piperidin-1-yl]-xanthines, the preparation thereof and their use as pharmaceutical compositions |
02 Nov, 2025
(10 months from now)
| Active |
US7407955 | 8-[3-amino-piperidin-1-yl]-xanthines, the preparation thereof and their use as pharmaceutical compositions |
02 May, 2025
(4 months from now)
| Active |
US8119648 | 8-[3-amino-piperidin-1-yl]-xanthines, the preparation thereof and their use as pharmaceutical compositions |
12 Aug, 2023
(1 year, 4 months ago)
| Expired |
US8178541 | 8-[3-amino-piperidin-1-yl]-xanthines, the preparation thereof and their use as pharmaceutical compositions |
12 Aug, 2023
(1 year, 4 months ago)
| Expired |
US6890898 | Method of regulating glucose metabolism, and reagents related thereto |
02 Feb, 2019
(5 years ago)
| Expired |
US7078381 | Method of regulating glucose metabolism, and reagents related thereto |
02 Feb, 2019
(5 years ago)
| Expired |
US7459428 | Method of regulating glucose metabolism, and reagents related thereto |
02 Feb, 2019
(5 years ago)
| Expired |
US6303661 | Use of dipeptidyl peptidase IV effectors for lowering the blood glucose level in mammals |
24 Apr, 2017
(7 years ago)
| Expired |
Discover which of these patents contain the active ingredient(API) of the drug, their family patents, along with litigation and legal activity details of these patents on Tradjenta's drug page
24. Trijardy Xr
Trijardy Xr is protected by 28 patents, out of which 3 have expired. Check out its patent list below.
Drug Patent Number | Drug Patent Title | Drug Patent Expiry | Status |
---|---|---|---|
US9949998
(Pediatric)
| Pharmaceutical composition, methods for treating and uses thereof |
11 Dec, 2034
(9 years from now)
| Active |
US10258637
(Pediatric)
| Pharmaceutical composition, methods for treating and uses thereof |
03 Oct, 2034
(9 years from now)
| Active |
US11090323
(Pediatric)
| Pharmaceutical composition, methods for treating and uses thereof |
03 Oct, 2034
(9 years from now)
| Active |
US9949998 | Pharmaceutical composition, methods for treating and uses thereof |
11 Jun, 2034
(9 years from now)
| Active |
US10258637 | Pharmaceutical composition, methods for treating and uses thereof |
03 Apr, 2034
(9 years from now)
| Active |
US11090323 | Pharmaceutical composition, methods for treating and uses thereof |
03 Apr, 2034
(9 years from now)
| Active |
US11833166 | Pharmaceutical composition, methods for treating and uses thereof |
03 Apr, 2034
(9 years from now)
| Active |
US10596120 | Pharmaceutical compositions |
07 Mar, 2032
(7 years from now)
| Active |
US11564886 | Pharmaceutical compositions |
07 Mar, 2032
(7 years from now)
| Active |
US10406172 | Pharmaceutical composition, methods for treating and uses thereof |
15 Jun, 2030
(5 years from now)
| Active |
US9155705 | DPP-IV inhibitor combined with a further antidiabetic agent, tablets comprising such formulations, their use and process for their preparation |
21 May, 2030
(5 years from now)
| Active |
US8551957
(Pediatric)
| Pharmaceutical composition comprising a glucopyranosyl-substituted benzene derivate |
14 Apr, 2030
(5 years from now)
| Active |
US8551957 | Pharmaceutical composition comprising a glucopyranosyl-substituted benzene derivate |
14 Oct, 2029
(4 years from now)
| Active |
US10022379 | DPP-IV inhibitor combined with a further antidiabetic agent, tablets comprising such formulations, their use and process for their preparation |
02 Apr, 2029
(4 years from now)
| Active |
US9415016 | DPP-IV inhibitor combined with a further antidiabetic agent, tablets comprising such formulations, their use and process for their preparation |
02 Apr, 2029
(4 years from now)
| Active |
US7579449
(Pediatric)
| Glucopyranosyl-substituted phenyl derivatives, medicaments containing such compounds, their use and process for their manufacture |
01 Feb, 2029
(4 years from now)
| Active |
US7579449 | Glucopyranosyl-substituted phenyl derivatives, medicaments containing such compounds, their use and process for their manufacture |
01 Aug, 2028
(3 years from now)
| Active |
US7713938
(Pediatric)
| Crystalline form of 1-chloro-4-(β-D-glucopyranos-1-yl)-2-[4-((S)-tetrahydrofuran-3-yloxy)-benzyl]-benzene, a method for its preparation and the use thereof for preparing medicaments |
15 Oct, 2027
(2 years from now)
| Active |
US8673927 | Uses of DPP-IV inhibitors |
04 May, 2027
(2 years from now)
| Active |
US9173859 | Uses of DPP IV inhibitors |
04 May, 2027
(2 years from now)
| Active |
US7713938 | Crystalline form of 1-chloro-4-(β-D-glucopyranos-1-yl)-2-[4-((S)-tetrahydrofuran-3-yloxy)-benzyl]-benzene, a method for its preparation and the use thereof for preparing medicaments |
15 Apr, 2027
(2 years from now)
| Active |
US8883805
(Pediatric)
| Process for the preparation of chiral 8-(3-aminopiperidin-1-yl)-xanthines |
26 May, 2026
(1 year, 5 months from now)
| Active |
US8883805 | Process for the preparation of chiral 8-(3-aminopiperidin-1-yl)-xanthines |
26 Nov, 2025
(11 months from now)
| Active |
US7407955
(Pediatric)
| 8-[3-amino-piperidin-1-yl]-xanthines, the preparation thereof and their use as pharmaceutical compositions |
02 Nov, 2025
(10 months from now)
| Active |
US7407955 | 8-[3-amino-piperidin-1-yl]-xanthines, the preparation thereof and their use as pharmaceutical compositions |
02 May, 2025
(4 months from now)
| Active |
US8119648 | 8-[3-amino-piperidin-1-yl]-xanthines, the preparation thereof and their use as pharmaceutical compositions |
12 Aug, 2023
(1 year, 4 months ago)
| Expired |
US8178541 | 8-[3-amino-piperidin-1-yl]-xanthines, the preparation thereof and their use as pharmaceutical compositions |
12 Aug, 2023
(1 year, 4 months ago)
| Expired |
US6488962 | Tablet shapes to enhance gastric retention of swellable controlled-release oral dosage forms |
20 Jun, 2020
(4 years ago)
| Expired |
Discover which of these patents contain the active ingredient(API) of the drug, their family patents, along with litigation and legal activity details of these patents on Trijardy Xr's drug page
25. Twynsta
Twynsta is protected by 1 patent, which has expired already. Check out its patent list below.
Drug Patent Number | Drug Patent Title | Drug Patent Expiry | Status |
---|---|---|---|
US5591762 | Benzimidazoles useful as angiotensin-11 antagonists |
07 Jan, 2014
(10 years ago)
| Expired |
Discover which of these patents contain the active ingredient(API) of the drug, their family patents, along with litigation and legal activity details of these patents on Twynsta's drug page
26. Viramune Xr
Viramune Xr is protected by 1 patent, which is still active. Check out its patent list below.
Drug Patent Number | Drug Patent Title | Drug Patent Expiry | Status |
---|---|---|---|
US8460704 | Extended release formulation of nevirapine |
12 Mar, 2029
(4 years from now)
| Active |
Discover which of these patents contain the active ingredient(API) of the drug, their family patents, along with litigation and legal activity details of these patents on Viramune Xr's drug page